Implantable prosthetic device comprising a cell expressing a channelrhodopsin

Patent metadata

Field	Value
Publication number	US-9829492-B2
Application number	US-201514822552-A
Country	US
Kind code	B2
Filing date	Aug 10, 2015
Priority date	Jul 22, 2005
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.

First claim

What is claimed is:

1. An implantable prosthetic device comprising a cell expressing a channelrhodopsin, wherein the channelrhodopsin comprises an amino acid sequence having at least about 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1, and wherein the cell is a pain pathway neuron, a peripheral neuron, a neuron of the anterior cingulate cortex, or a neuron of the subgenual cingulate cortex.

2. The implantable device of claim 1 , wherein the channelrhodopsin comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1.

3. The implantable device of claim 1 , wherein the cell is a neuron of the subgenual cingulate cortex.

4. The implantable device of claim 1 , wherein the cell is a pain-pathway neuron.

5. The implantable device of claim 1 , wherein the cell is a peripheral neuron.

6. The implantable device of claim 1 , wherein the cell is a neuron of the anterior cingulate cortex.

7. The implantable device of claim 1 , further comprising an implantable light source.

8. The implantable device of claim 1 , wherein the channelrhodopsin is encoded by a nucleotide sequence present in a viral vector, wherein the channelrhodopsin-encoding nucleotide sequence is operably linked to a cell-specific promoter.

9. The implantable device of claim 8 , wherein the cell-specific promoter is a somatostatin promoter, a parvalbumin promoter, a GABAα6 promoter, a calbindin promoter, or an EF1-alpha promoter.

10. The implantable device of claim 8 , wherein the viral vector is a lentivirus vector or a retroviral vector.

11. A system comprising:
a) an implantable prosthetic device comprising a cell expressing a channelrhodopsin, wherein the channelrhodopsin comprises an amino acid sequence having at least about 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1, and wherein the cell is a pain pathway neuron, a peripheral neuron, a neuron of the anterior cingulate cortex, or a neuron of the subgenual cingulate cortex; and
b) an implantable light source.

12. The system of claim 11 , wherein
wherein the channelrhodopsin comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1.

13. The system of claim 11 , wherein the cell is a pain-pathway neuron.

14. The system of claim 11 , wherein the cell is a peripheral neuron.

15. The system of claim 11 , wherein the cell is a neuron of the subgenual cingulate cortex.

16. The system of claim 11 , wherein the cell is a neuron of the anterior cingulate cortex.

17. The system of claim 11 , wherein the channelrhodopsin is encoded by a nucleotide sequence present in a viral vector, wherein the channelrhodopsin-encoding nucleotide sequence is operably linked to a cell-specific promoter.

18. The system of claim 17 , wherein the cell-specific promoter is a somatostatin promoter, a parvalbumin promoter, a GABAα6 promoter, a calbindin promoter, or an EF1-alpha promoter.

19. The system of claim 17 , wherein the viral vector is a lentivirus vector or a retroviral vector.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Boyden Edward S

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P5/02

  of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title